Genmab H1 FY26 operating profit rises 1% to USD 555 million; revenue increases 25% to USD 2.05 billion
G
GMAB• First-half results and guidance
- Genmab revenue rose 25% to USD 2.05 billion in the first half of 2026.
- Operating profit edged up to USD 555 million; adjusted operating profit (non-IFRS) increased to USD 656 million.
- Royalty revenue climbed 24% to USD 1.71 billion, driven by higher DARZALEX and Kesimpta royalties.
- Global net sales of EPKINLY/TEPKINLY rose 48% to USD 312 million; cost of product sales increased 51% to USD 149 million.
- Raised 2026 revenue guidance to USD 4.33-4.53 billion; highlighted positive Phase 3 epcoritamab data in relapsed/refractory DLBCL.
